Compare Costco Wholesale Corporation (COST) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs TransMedics Group Inc — how do they compare? Costco Wholesale Corporation trades at $949.7 (market cap $418.79B), while TransMedics Group Inc trades at $86.51 (market cap $3.10B). The key difference: Costco Wholesale Corporation is far larger — about 135.1× TransMedics Group Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| COST | TMDX | |
|---|---|---|
Market Cap | $418.79B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $1.09K | $150.42 |
52-Week Low | $849.63 | $61.99 |
Enterprise Value | $406.93B | $3.49B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $944.32, down 0.88% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong March sales growth of 11.3% year-over-year (Business Wire, April 8, 2026) and has consistently beaten earnings expectations in recent quarters. Revenue reached $275.24 billion in 2025 with net income of $8.10 billion, though valuation ratios remain elevated with a P/E of 47.5. Analyst consensus is strongly bullish with 65.5% buy ratings and a $1,120 price target.
Costco's outlook remains positive due to membership fee increases and expanding warehouse footprint, but the stock faces risks from high valuation multiples and competitive retail pressures. The current price sits near key support at $938, with upside potential to resistance at $950. Institutional buying activity continues, though technical indicators suggest near-term consolidation may occur before further gains.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
